Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products

Journal of Managed Care Pharmacy

Volumn 21, Issue 1, 2015, Pages 23-34

  Baldziki, Mike ^a   Ball, Phil ^b   Brown, Jeff ^c   Chan, Hungching ^d   Craig Cheetham, T ^e   Conn, Thomas ^a   Daniel, Gregory W ^f   Hendrickson, Mark ^g   Hilbrich, Lutz ^h   Johnson, Ayanna ⁱ   Miller, Steven B ^j   Moore, Tom ^k   Motheral, Brenda ^l   Priddy, Sarah A ^m   Raebel, Marsha A ^e   Randhawa, Gurvaneet ⁿ   Surratt, Penny ^o   Walraven, Cheryl ^p   Jeff White, T ^q   Zheng, Yi ^p   Bruns, Kevin ^r   Carden, Mary Jo ^r   Dragovich, Charlie ^r   Eichelberger, Bernadette ^r   Rosato, Edith ^r   Sega, Todd ^r   more..

^a Armada   (United States)

^b Actavis Inc   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d OptumInsights   (United States)

^e KAISER PERMANENTE   (United States)

^f Brookings Engelberg Center for Health Care Reform   (United States)

^g Generic Pharmaceutical Association   (United States)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ National Consumers League   (United States)

^j Express Script Inc   (United States)

^k AMGEN INC   (United States)

^l Artemetrx   (United States)

^m Humana Comprehensive Health Insights ^*  (United States)

ⁿ AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^o Humana   (United States)

^p AETNA   (United States)

^q WellPoint   (United States)

^r Academy of Managed Care Pharmacy   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; FILGRASTIM; HUMAN GROWTH HORMONE; INFLIXIMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN;

ARTICLE; DATA ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; INFORMATION PROCESSING; MANAGED CARE; COMPARATIVE EFFECTIVENESS; CONSENSUS; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH INSURANCE; INTEGRATED HEALTH CARE SYSTEM; MANAGED CARE ORGANIZATION; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; TOTAL QUALITY MANAGEMENT; ORGANIZATION AND MANAGEMENT; PHARMACY; PROCEDURES; UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; DATA COLLECTION; DRUG APPROVAL; HUMANS; PHARMACEUTICAL SERVICES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84925337145     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Patient Protection and Affordable Care Act. Public Law 111-148: 124 Statute 119. 111th Congress. March 23, 2010. Congress.gov. Available at: http://beta.congress.gov/111/plaws/publ148/PLAW-111publ148.pdf. Accessed April 21, 2014.
2. U.S. Food and Drug Administration. Guidance for industry: scientific consideration in demonstrating biosimilarity to a reference product. February 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed April 21, 2014.
3. Express Scripts Inc. The 2013 drug trend report. April 2014. Available at: http://lab.express-scripts.com/~/media/pdfs/drug%20trend%20report/express%20scripts%202013%20drug%20trend%20report.ashx. Accessed April 21, 2014.
4. Dalgaard K, Evers M, de Silva JS. Biosimilars seven years on: where are we and what's next? McKinsey and Company. February 2013. Available at: http://www.mckinsey.com/Search.aspx?q=Biosimilars&l=Insights%20%26%20Publications. Accessed April 21, 2014.
5. Miller S. Defining biosimilars and their effect on healthcare. Presented at: Meeting of the AMCP Task Force on Biosimilar Collective Intelligence System: Utilizing Data Consortiums to Prove Safety and Effectiveness of Biosimilars; Alexandria, VA; November 12, 2013.
6. Motheral B. Specialty drug trend across the medical and pharmacy benefit. Artemetrix. 2013. Available at: http://www.artemetrx.com/docs/ARTEMETRX_Specialty_Trend_Rpt.pdf. Accessed April 21, 2014.
7. Pharmaceutical Research and Manufacturers of America. Medicines in development: biologics. 2013. Available at: http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf. Accessed April 21, 2014.
8. CenterWatch. FDA approved drugs. November 2013. Available at: http://www.centerwatch.com/drug-information/fda-approvals/. Accessed April 21, 2014.
9. Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Pharm. 2013;19(9 Suppl A):S1-S19. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=17383.
10. U.S. Food and Drug Administration. FDA approves new treatment for severe neutropenia in certain cancer patients. News and Events. August 29, 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317392.htm. Accessed April 21, 2014.
11. Mikhail A, Farouk M. Epoetin biosimilars in Europe: five years on. Adv Ther. 2013;30(1):28-40.
12. European Medicines Agency. Biosimilar medicines. November 19, 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp&mid=WC0b01ac0580281bf0. Accessed April 21, 2014.
13. Brown J. Reviewing current landscape of existing data consortiums: how they are being used, what they uncover, how they function-the Mini-Sentinel example. Presented at: Meeting of the AMCP Task Force on Biosimilar Collective Intelligence System: Utilizing Data Consortiums to Prove Safety and Effectiveness of Biosimilars; Alexandria, VA; November 12, 2013.
14. Southworth MR, Reichman ME, Unger ER. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272-74.
15. U.S. Food and Drug Administration. FDA drug safety communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. July 3, 2013. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM359496.pdf. Accessed April 21, 2014.
16. Mini-Sentinel. Overview and description of the common data model v4.0. 2014. Available at: http://www.mini-sentinel.org/work_products/Data_Activities/Mini-Sentinel_Common-Data-Model.pdf. Accessed April 21, 2014.
17. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):S23-S31.
18. Marsolo K. Approaches to facilitate institutional review board approval of multicenter research studies. Med Care. 2012;50(Suppl):S77-S81.
19. Hersh WR, Weiner MG, Embi PJ, et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care. 2013;51(8 Suppl 3):S30-S37.
20. Randhawa G. The EDM Forum approach to overcome traditional barriers in using electronic data sources for CER and QI. Presented at: Meeting of the AMCP Task Force on Biosimilar Collective Intelligence System: Utilizing Data Consortiums to Prove Safety and Effectiveness of Biosimilars; Alexandria, VA; November 12, 2013.
21. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16(3):336-41.
22. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Safety. 2007;16(12):1274-84.
23. Priddy SA. Distributed data networks: meeting MCO knowledge management concerns-security, privacy, and access. Presented at: Meeting of the AMCP Task Force on Biosimilar Collective Intelligence System: Utilizing Data Consortiums to Prove Safety and Effectiveness of Biosimilars; Alexandria, VA; November 12, 2013.
24. Curtis JR, Xie F, Chen R, et al. Identifying newly approved medications in Medicare claims data: a case study using tocilizumab. Pharmacoepidemiol Drug Saf. 2013;22(11):1214-21.